EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte Studie

Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial

Nanocurcumin-Supplementierung verbessert die Lungenfunktion bei Patient:innen mit schwerer COPD: randomisierte, doppelblinde, placebokontrollierte klinische Studie

Mahdieh Zare'i, Masoumeh Rabieepour, Rasoul Ghareaghaji, Rasoul Zarrin iD, Amir Hossein Faghfouri iD

Phytotherapy Research · 2024-03 · 38 (3) · 1224-1234

DOI: 10.1002/ptr.8114 ↗

Auf einen Blick

Bei 60 Patient:innen mit COPD Stadium 3 und 4 verbesserte Nanocurcumin über 3 Monate Entzündungs- und Atemparameter gegenüber Placebo. IL-6 sank, FEV1, FVC und FEV1/FVC stiegen.

Fragestellung

Wirkt 80 mg Nanocurcumin über 3 Monate auf Atemparameter und IL-6 bei Patient:innen mit schwerer COPD?

Methode

Doppelblinde, placebokontrollierte randomisierte klinische Studie mit 60 Patient:innen; 80 mg Nanocurcumin oder Placebo für 3 Monate.

Ergebnisse

IL-6 nahm unter Nanocurcumin signifikant ab (p < 0,001). FEV1 (p < 0,001), FVC (p = 0,003) und FEV1/FVC (p < 0,001) stiegen gegenüber Placebo. Gewicht, BMI und systolischer Blutdruck verbesserten sich ebenfalls.

Schlussfolgerung der Autor:innen

Nanocurcumin scheint günstige Effekte auf den Entzündungsstatus und respiratorische Indizes bei Patient:innen mit schwerer COPD zu haben.

Kernaussagen

  • IL-6 sank unter Nanocurcumin signifikant
  • FEV1, FVC und FEV1/FVC stiegen gegenüber Placebo
  • Auch Gewicht, BMI und systolischer Blutdruck verbesserten sich

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Randomisierte kontrollierte Studie in Phytotherapy Research, published online on 2024-01-04. Written by Mahdieh Zare'i and 4 co-authors. Institution: Department of Nutrition, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran. Major MEDLINE topics: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Curcumin. Cited 22 times so far (Crossref); 64 references. Funded by: Urmia University of Medical Sciences.

Auf einen BlickAbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Considering the anti‐inflammatory properties of curcumin, the present study was designed to investigate the effect of nano‐curcumin on respiratory indices and interleukin‐6 (IL‐6) levels in severe chronic obstructive pulmonary disease (COPD) patients as a common pulmonary disease causing restricted airflow and breathing problems. In the current double‐blind placebo‐controlled randomized clinical trial study, 60 patients with stages 3 and 4 COPD were randomly assigned into 80 mg nano‐curcumin ( n = 30) and placebo groups ( n = 30) for 3 months. The effect of nano‐curcumin on pulmonary function was evaluated by the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC) ratio. IL‐6 serum level, blood pressure, and anthropometric indices were also measured. Nano‐curcumin supplementation led to a significant decrease in IL‐6 level ( p < 0.001) and an increase in FEV1 ( p < 0.001), FVC ( p = 0.003), and FEV1/FVC ( p < 0.001) compared to placebo at the endpoint. Nano‐curcumin had a significantly increasing effect on weight and body mass index compared to the placebo group ( P ANCOVA adjusted for baseline values = 0.042). There was a meaningful improvement in systolic blood pressure in the nano‐curcumin group compared to the placebo group ( P ANCOVA adjusted for baseline values = 0.026). There was no significant difference between the two groups in terms of waist circumference, waist‐to‐hip ratio, and diastolic blood pressure ( P ANCOVA adjusted for baseline values >0.05). Nano‐curcumin supplement seems to have favorable effects on inflammation status and respiratory indices of patients with severe COPD.

Subjects

MeSH terms (MEDLINE)

Pulmonary Disease, Chronic ObstructiveLung DiseasesCurcuminHumansInterleukin-6LungDietary SupplementsDouble-Blind Method

Author keywords

COPDcurcumininterleukin-6respiratory function tests

Substances

Interleukin-6Curcumin

Authors and institutions

  • Department of Nutrition, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
  • Department of Internal Medicine, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
  • Department of Epidemiology and Biostatistics, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
  • Maternal and Childhood Obesity Research Center, Urmia University of Medical Sciences, Urmia, Iran.

ORCID profiles: Rasoul Zarrin, Amir Hossein Faghfouri

Funding

  • Urmia University of Medical Sciences

Cite

APA

Zare'i, M., Rabieepour, M., Ghareaghaji, R., Zarrin, R., & Faghfouri, A. H. (2024). Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial. Phytotherapy Research, 38(3), 1224-1234. https://doi.org/10.1002/ptr.8114

Vancouver

Zare'i M, Rabieepour M, Ghareaghaji R, Zarrin R, Faghfouri AH. Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial. Phytotherapy Research. 2024;38(3):1224-1234. doi:10.1002/ptr.8114

BibTeX
@article{Zarei2024,
  author = {Zare'i, Mahdieh and Rabieepour, Masoumeh and Ghareaghaji, Rasoul and Zarrin, Rasoul and Faghfouri, Amir Hossein},
  title = {Nanocurcumin supplementation improves pulmonary function in severe COPD patients: A randomized, double blind, and placebo‐controlled clinical trial},
  journal = {Phytotherapy Research},
  year = {2024},
  volume = {38},
  number = {3},
  pages = {1224--1234},
  doi = {10.1002/ptr.8114}
}
Start for free →